National regulations and guidelines on naming of medicinal products regulate the criteria that applicants or marketing authorization holders must fulfill when forming the name of a medicinal product. They are therefore a guide for applicants and marketing authorization holders to correctly form the name of the medicinal product for the Member State in which they wish to place the medicinal product on the market. This research is aimed at identifying differences between regulations/guidelines, ie at determining the criteria that all regulations/guidelines should contain in order to constitute good guides for applicants and marketing authorization holders, through a structured review of all available regulations or guidelines of the Member States of the European Economic Area. The aim was also to survey the understanding of the meaning of qualifiers in the names of medicinal products in the general population and amongst the health professionals in the Republic of Croatia. This research was conducted to assess the respondents' understanding of the meanings of certain qualifiers and thus to conclude whether the qualifiers provided by the Croatian national guideline are appropriate for the use in naming of medicines in the Republic of Croatia. The research showed that numerous important criteria are not represented in most guidelines and that they mostly differ significantly. Many guidelines are very short, with a small number of prescribed requirements to be fulfilled when creating drug names. Also, the analysis of the survey showed that the respondents of both groups understand the meaning of all qualifiers quite well and that, after the given explanation and example of the name of the medicinal product where a certain qualifier is found, they assessed them as perfectly understandable. Only the "MITE" qualifier was not described accurately and precisely enough by either of the groups, so its application and regulation by the guideline on naming of medicinal products in the Republic of Croatia should be re-examined and discussed.